Plain-English translation of NCT07230496 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety study testing a new injectable medication called LAE103, designed to help with weight management. Researchers will give some participants LAE103 alone and others LAE103 combined with another experimental medication (LAE102) to see how safe it is, how well the body tolerates it, and how the body processes it. The study will also look at how these medications affect the body's weight-related markers.
Current weight management options have limitations, and researchers are exploring new biological approaches that might work differently than existing treatments. This early trial will help determine if this medication is safe enough and promising enough to test further in larger groups of people.
You likely qualify if…
You likely don't qualify if…
You would receive either the new medication or a placebo (saline injection) as a subcutaneous injection under your skin. Depending on which part of the study you join, you might receive a single injection or multiple injections over time. You would need to attend several study visits where researchers will monitor your safety through blood tests, heart monitoring, and physical exams, and track how your body processes the medication over days or weeks.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Australia